Continuing Education Activity

Quinidine, a stereoisomer of quinine, is derived from the bark of the South American cinchona tree. Quinidine is regarded as one of the earliest known antiarrhythmics, and it serves as a class 1a antiarrhythmic drug and an antimalarial agent. An interprofessional approach involving specialties such as cardiology, rheumatology, infectious disease, intensive care, and nursing is necessary when using this drug. Quinidine is a medication primarily utilized to manage and treat specific arrhythmias and malaria in patients. This activity reviews quinidine's indications, actions, and contraindications, emphasizing its significance as a valuable agent for treating certain arrhythmias and malaria. In addition, this activity will focus on elucidating the mechanism of action, adverse event profile, and other crucial factors, including pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional healthcare teams to effectively manage conditions related to arrhythmia and malaria in patients.

Objectives:

• Identify the pharmacological properties and mechanisms of action of quinidine as a Class 1a antiarrhythmic and antimalarial agent.
• Screen patients with arrhythmias to identify suitable candidates for quinidine therapy based on their medical history, EKG findings, and overall health status.
• Integrate quinidine into treatment plans for patients with specific arrhythmias, ensuring proper dosing, administration, and monitoring.
• Communicate with patients about the benefits, risks, and potential adverse effects of quinidine treatment.

Indications

Quinidine, a stereoisomer of quinine, is derived from the bark of the South American cinchona tree. Quinidine serves as a class 1a antiarrhythmic drug and an antimalarial agent. Quinidine is a medication mainly used for treating and managing arrhythmias in patients.[1] 

Quinidine is approved by theU.S. Food and Drug Administration (FDA) for the treatment of the indications listed below.

• Plasmodium falciparum malaria: Quinidine is recognized as an effective treatment for severe and complicated malaria, either as a standalone therapy or combined with an exchange transfusion.[2]
• Atrial fibrillation/flutter to sinus rhythm conversion
• Reduction of frequency of atrial fibrillation/flutter relapse
• Ventricular arrhythmia suppression
• Pseudobulbar affect: The FDA approved the combination of dextromethorphan and quinidine capsules to treat the pseudobulbar affect.[3]

Quinidine is currently under investigation for its potential role in managing KCNT1 (potassium sodium-activated channel subfamily T member 1)-related epileptic disorders, and it has already received FDA approval for this indication.[4]

Mechanism of Action

Quinidine is used as an antiarrhythmic agent and an antimalarial agent. The mechanism of action varies depending on the indication. 

Like other class 1a antiarrhythmic agents, quinidine inhibits the fast inward sodium current, leading to a depression of phase 0 of the action potential. This mechanism dampens the excitability of cardiac muscles, ultimately resulting in the prolongation of the action potential duration and a decrease in automaticity. Quinidine exhibits a "use-dependent block" effect on the fast inward sodium current, which implies that the drug's impact increases during higher heart rates and decreases during lower heart rates.[5]

Quinidine also reduces potassium efflux during repolarization, inhibiting the slow, delayed rectifier potassium current. Furthermore, it displays a pattern of "reverse-use dependence," resulting in less current suppression at more frequent depolarizations. In addition, quinidine impacts calcium transport across cell membranes. These combined effects contribute to the prolongation of the QRS interval.[6] 

Quinidine exerts a parasympatholytic effect, resulting in an increase in sinus rate. In addition, it prolongs the QRS complex and the QTc interval while having a negligible effect on the PR interval.[6][7]

Quinidine functions as an effective antimalarial agent by targeting the erythrocytic stage of the Plasmodium species. The drug achieves this by accumulating within the parasite's food vacuole and forming a complex with heme, thereby inhibiting crystallization within the same compartment. Consequently, the inhibited heme polymerase activity leads to the accumulation of cytotoxic-free heme. Moreover, quinidine exhibits anticholinergic activity as an additional pharmacological feature.

Pharmacokinetics

• Absorption: Quinidine exhibits a time-to-peak plasma concentration of approximately 2 hours, whereas the extended-release versions typically take 3 to 4 hours to reach peak levels. Notably, sustained-release quinidine gluconate has been found to yield higher serum concentrations than sustained-release quinidine sulfate.
• Distribution: Quinidine shows a substantial volume of distribution (2 to 3 L/kg), with an increased volume in individuals with cirrhosis and a decreased volume in individuals with congestive heart failure (CHF). This medication primarily binds to alpha-1 acid glycoprotein, which increases when the body is under stress. This process leads to elevated serum levels of total quinidine during acute myocardial infarction. However, the drug's unbound (active) form may remain within the normal range. In addition, quinidine achieves higher concentrations in the heart, liver, and kidneys.
• Metabolism: Quinidine undergoes hepatic metabolism primarily through hydroxylation reactions mediated by cytochrome P450 enzymes (60% to 80%). These reactions form active compounds, notably the essential antiarrhythmic agent 3-hydroxy-quinidine (3HQ). Adjusting the medication dosage is necessary in cases of hepatic impairment to ensure optimal treatment outcomes.
• Excretion: The elimination half-life of quinidine increases with age and in conditions such as cirrhosis and CHF. Less than 20% of the drug is excreted unchanged in the urine, and dosage adjustment may be required only in cases of severe renal impairment.[8][7]

Administration

Quinidine is available in both parenteral and oral formulations.

Dosage

Parenteral: Quinidine is available as an injectable dose administered via the intravenous (IV) route in its gluconate preparations.

Oral: Quinidine tablets are available in both immediate-release and extended-release formulations. Immediate-release formulations are available in tablets of 200 and 300 mg (quinidine sulfate salt). Each 200 mg tablet contains 166 mg of quinidine base, and each 300 mg tablet contains 249 mg of quinidine base. The extended-release preparations are available in 324 mg (quinidine gluconate salt) tablets, with each tablet equivalent to 202 mg of quinidine base. The patients using the extended-release preparations are advised to swallow the whole pill without chewing, crushing, or breaking the tablet. 

Dosage Regimens

Atrial fibrillation/atrial flutter to sinus rhythm conversion: The dosage regimens for atrial fibrillation/atrial flutter to sinus rhythm conversion are available in 2 formulations as listed below.

• Oral immediate-release formulation: The initial therapy involves administering 2 tablets of 200 mg each every 6 hours to the patients. The dose may be cautiously increased if the desired pharmacological conversion is not achieved after 4 to 5 doses.
• Oral extended-release formulation: For the first treatment option, patients are administered 2 tablets of 324 mg each (equivalent to 403 mg of quinidine base) every 8 hours. If the desired pharmacological conversion is not achieved after 3 or 4 doses, the dose may be increased cautiously. As an alternative regimen, patients may have been prescribed 1 tablet (equivalent to 202 mg of quinidine base) every 8 hours for 2 days, followed by 2 tablets (equivalent to 403 mg of quinidine base) every 12 hours for 2 days, and, finally, 2 tablets (equivalent to 403 mg of quinidine base) every 8 hours for up to 4 days. For the final 4-day treatment plan, the lower dose may be opted at the physician's discretion.

During any of these regimens, if at any time the QRS complex or QTC interval widens to 130% of its pre-treatment duration, the QTC interval is longer than 500 ms, P waves disappear, or the patient experiences significant tachycardia, bradycardia, or hypotension, the quinidine therapy should be discontinued immediately.

Reduction of atrial fibrillation/flutter relapse: The dosage regimens for reduction of atrial fibrillation/flutter relapse are available in 2 formulations as listed below.

• Oral immediate-release formulation: The initial therapy involves administering 1 tablet (equivalent to 166 mg of quinidine base) every 6 hours. If the regimen is well tolerated and the serum quinidine level remains within the therapeutic index range, the dose may be cautiously increased to achieve the desired pharmacological effect.
• Oral extended-release formulation: Patients may have been administered 1 tablet (equivalent to 202 mg of quinidine base) every 8 or 12 hours for the first treatment option. If the regimen is well-tolerated and the serum quinidine level remains within the therapeutic index range, the dose may be cautiously increased to achieve the desired pharmacological effect.

During any of these regimens, if at any time the QRS complex or QTC interval widens to 130% of its pre-treatment duration, the QTC interval is longer than 500 ms, P waves disappear, or the patient experiences significant tachycardia, bradycardia, or hypotension, the total daily dose of quinidine should be reduced.

Ventricular arrhythmias suppression: The dosage regimens for ventricular arrhythmias suppression have not been extensively studied. However, these regimens have typically been similar to those described above for treating atrial fibrillation. Therefore, this therapy should be carefully managed and optimized based on the results obtained from programmed electrical stimulation or Holter monitoring, whenever possible, along with exercise testing.

Brugada syndrome and short QT syndrome: In the management of ventricular arrhythmias associated with Brugada syndrome and short QT syndrome, the American Heart Association/American College of Cardiology/Heart Rhythm Society (AHA/ACC/HRS) guidelines recommend administering an IV loading dose of 800 mg in 50 mL at a rate of 50 mg/min.[6]

Pseudobulbar affect: The initial treatment involves administering a fixed dose combination of 10 mg quinidine sulfate and 20 mg dextromethorphan once daily for 7 days. Subsequently, the daily dose is increased to 1 capsule every 12 hours.[3]

Treatment of P falciparum malaria: According to the manufacturer label, the dosage regimen for quinidine sulfate tablets should be similar to the regimen described in the package insert of quinidine gluconate injection. Notably, a few years ago, the sole manufacturer of quinidine IV products discontinued this product in the United States.[2]

Specific Patient Population 

• Patient with hepatic impairment: The manufacturer label does not provide specific dosage adjustment guidance for patients with hepatic impairment. However, as most quinidine is metabolized and eliminated via cytochrome 3A4, caution should be exercised when using the drug in these patients. 
• Patient with renal impairment: The manufacturer label does not offer dosage adjustment guidance for patients with renal impairment. However, as 20% of quinidine is eliminated in the urine, the drug should be used with caution in these patients, and a lower dose may be necessary, especially in patients with severe renal impairment. 
• Pregnant considerations: The FDA previously categorized quinidine as a medication belonging to pregnancy category C. Both quinidine and its metabolites have the potential to cross the placental membrane and be detected in the neonatal serum. As such, caution should be exercised when prescribing quinidine to pregnant individuals.
• Breastfeeding considerations: To ensure the safety of nursing mothers, the manufacturer advises against quinidine therapy due to the presence of quinidine in breast milk.[9]
• Pediatric patients: The safety and efficacy of quinidine for antiarrhythmic use have not been established in the pediatric patient population. 
• Geriatric patients: The safety and efficacy of quinidine have not been systematically studied in this patient population.

Adverse Effects

Although quinidine is effective in managing specific conditions, the drug is associated with various adverse effects affecting bodily systems, as listed below.

Cardiovascular: Quinidine is widely recognized as one of the most common drugs that cause a prolongation of the QT interval. In some cases, this prolonged QT interval may progress to pleomorphic tachyarrhythmia, known as torsades de pointes (TdP), affecting approximately 1% to 3% of patients. Cardiac adverse effects are more likely to occur in patients with lower heart rates and hypokalemia. The QT interval prolongation is more pronounced in females than males, and the onset of severe QT prolongation may indicate drug toxicity. Palpitations, angina pectoris, new or worsened cardiac arrhythmia, and syncope are all possible signs of these cardiovascular effects.[10][11]

Central nervous system: Quinidine crosses the blood-brain barrier through passive diffusion and an active transport system, potentially leading to adverse effects such as dizziness, fatigue, headache, disturbed sleep, nervousness, and ataxia.[12]

Dermatological: Quinidine use has been associated with the occurrence of skin rash.[13]

Gastrointestinal: Quinidine use has been linked to potential adverse effects such as hepatotoxicity, diarrhea, digestive distress, nausea and vomiting, and esophagitis.[13]

Neuromuscular and skeletal: Quinidine use may lead to neuromuscular and skeletal effects, including weakness and tremors.[14]

Ophthalmological: Quinidine use has been associated with potential visual disturbances.[15]

Other adverse effects of quinidine are listed below.

• Fever and hypersensitivity reactions occur in individuals who are allergic to the drug.
• Hypokalemia or hypomagnesemia can potentially lead to drug toxicity when taking quinidine.
• Hemolysis is a possible occurrence in patients with G6PD deficiencies when using quinidine.
• Cinchonism, which is associated with quinidine as it is a stereoisomer of quinine derived from the bark of the cinchona tree, can manifest with symptoms such as tinnitus, sensorineural hearing loss, blurring of vision, diplopia, photophobia, confusion, headache, delirium, and decreased hearing to profound deafness.
• Quinidine use may rarely lead to drug-induced lupus erythematosus (DILE).[16]
• Quinidine use has been associated with the development of Sjogren's syndrome.
• Blackwater fever, a condition linked to quinidine, is characterized by a triad of massive hemolysis, hemoglobinemia, and hemoglobinuria, potentially leading to acute kidney injury, jaundice, and, in severe cases, even death.[2][17]

Drug Interactions

• Quinidine is an inhibitor of CYP450 enzymes and has the potential to interact with drugs that are metabolized by this enzyme system.
• Quinidine has been demonstrated to reduce digoxin's total clearance by 30%, renal clearance by 32%, and nonrenal clearance by 29%.[18] This action is explained by quinidine's property of displacing digoxin from protein-binding sites, which can result in altered clearance. Furthermore, the reduction in renal clearance may be attributed to quinidine's inhibition of the renal secretion of digoxin.[19]
• Erythromycin has been demonstrated to decrease quinidine clearance, leading to increased serum concentrations and potentially predisposing patients to quinidine toxicity. Therefore, when administering erythromycin concurrently with quinidine, it is advisable to monitor patients' serum potassium and magnesium levels and perform timely electrocardiograms (EKGs) to detect any signs of possible toxicity.[20]
• Phenobarbital and phenytoin have been demonstrated to reduce the half-life of quinidine by half, potentially by increasing its metabolism through the induction of CYP450 enzymes.[21]
• Cimetidine competes for the renal tubular secretion of quinidine in both its unchanged form and metabolites, leading to increased quinidine concentration in the plasma.[22]
• QT-prolonging drugs, such as clarithromycin and amiodarone, increase TdP risk when administered with quinidine.[7]

Contraindications

The contraindications of quinidine include the following:

• Thrombocytopenia
• Thrombocytopenic purpura
• Hypersensitivity to quinine, mefloquine, quinidine, or any component used in the drug preparation.
• Heart block greater than first degree.
• Concurrent use with amprenavir, cisapride, ritonavir, fluoroquinolones, or other drugs known to prolong the QT interval
• Congenital long QT interval
• AV block, as concurrent use of the drug can progress to a complete heart block [6]

Precautions

• Patients on digoxin may experience higher plasma quinidine levels and a shorter half-life on low doses than those not taking quinidine. 
• Pediatric patients typically require a higher dose of quinidine compared to adults.[23]
• The advanced-age population exhibits reduced clearance of quinidine and an increased drug half-life, potentially leading to an increased risk of toxicity. Therefore, appropriate adjustment of drug dosages is necessary for this age group.[24]
• In patients with CHF, dosage adjustment of quinidine is recommended, as regular drug dosing may result in abnormally high serum concentrations.[25]
• Quinidine falls under the FDA pregnancy risk category C and is generally not considered safe during pregnancy. The drug should only be considered when the potential maternal benefit justifies the potential risk to the fetus.
• Although quinidine concentrations in breast milk are lower than in maternal plasma, quinidine does pass into breast milk. Breastfeeding neonates can develop serum quinidine concentrations lower than those in the mother. Neonates may experience toxicity even with lower plasma quinidine levels.
• The anticholinergic activity of quinidine can potentially exacerbate the symptoms of myasthenia gravis in patients. In addition, quinidine may interact with other drugs used to treat the disease.
• Caution is advised when using quinidine in patients with asthma and other allergic conditions, as these conditions can mask hypersensitivity reactions to the drug.

Box Warning

• Quinine should not be used to manage nocturnal leg cramps due to the risk of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS). A triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury characterizes HUS. TTP presents as a pentad of fever, neurologic dysfunction, microangiopathic hemolytic anemia, thrombocytopenia, and a high risk of chronic kidney disease.[26][27]
• Due to the increased mortality risk, the ACC/AHA/HRS does not approve of using quinidine to treat atrial fibrillation.[28]

Safe Practice

• Quinidine can sometimes be confused with clonidine and quinine. For safer medication administration, it is recommended to use tall-man lettering.[29]
• Adjustment of dosages may be necessary for patients with hepatic and renal disorders.
• Caution should be exercised when administering quinidine with drugs known to prolong the QT interval, such as thiazide diuretics, ondansetron, opioids, fluoroquinolones, risperidone, sotalol, antihistamines, tricyclic antidepressants, macrolides (erythromycin), and selective serotonin reuptake inhibitors (SSRIs).[30]

Monitoring

Routine EKG monitoring for QT interval and QRS changes and complete blood count (CBC), liver, and renal function testing should be conducted regularly when administering quinidine to patients via IV infusion or for an extended duration.[6] Monitoring and correcting for electrolyte abnormalities known to cause QT prolongation, such as hypokalemia, hypomagnesemia, and hypocalcemia, are essential. Using the Tisdale risk score can be a valuable strategy to screen for potential QT interval issues and help with risk mitigation.[30]

Toxicity

Quinidine is widely known for its potential toxicity, leading to QT prolongation, and it can trigger TdP, a life-threatening arrhythmia. As the condition can be fatal, it requires immediate management, including discontinuing the drug, closely monitoring cardiac and electrolyte levels (potassium and magnesium), and addressing any underlying hypoxia. Clinicians can effectively manage TdP by promptly administering magnesium sulfate and terminating prolonged episodes through electrical cardioversion. In refractory cases, isoproterenol or transvenous pacing may be the treatment options. In addition, hypotension can be addressed with IV fluids, and norepinephrine might be required in refractory cases.[31]

Hepatoxicity

Chronic therapy with quinidine has been linked to acute hypersensitivity reactions, including hepatic involvement. The responses typically manifest within 1 to 2 weeks after treatment. Clinical features include fatigue, vomiting, muscle aches, arthralgia, and high fever. Blood testing at an early stage reveals elevated serum aminotransferase and alkaline phosphatase levels, along with mild jaundice, which may persist for a few days even after discontinuing quinidine. The pattern of serum enzyme elevations is typically cholestatic or mixed, characterized by an increase in alkaline phosphatase levels and mild jaundice.

Clinical features of hypersensitivity are often characterized by arthralgia and fever. Liver biopsies typically reveal small epithelioid granulomas characteristic of systemic hypersensitivity reactions. As previously stated, hepatotoxicity occurs due to a hypersensitive reaction, and there is no indication of direct hepatotoxicity. To manage the situation, it is necessary to discontinue taking quinidine immediately. As hypersensitivity reactions are generally mild and self-resolving, corticosteroids should be avoided.[32]

Enhancing Healthcare Team Outcomes

Quinidine, one of the oldest drugs for arrhythmia management, remains valuable in treating conditions like early repolarization syndrome, Brugada syndrome, idiopathic ventricular fibrillation, and specific infections such as P falciparum malaria. An interprofessional team approach involving physicians, mid-level practitioners, nurses, cardiologists, rheumatologists, and pharmacists is essential to detect and manage potentially fatal drug toxicity effectively.

The team of cardiologists is essential in administering quinidine therapy, as this drug is utilized as either an antiarrhythmic or proarrhythmic agent. Due to the potential of quinidine to cause a lupus-like syndrome, rheumatologists are involved in the treatment process. Meanwhile, infectious disease specialists also play an essential role in managing severe malaria cases. Nurses are critical in ensuring accurate drug administration and monitoring for any adverse effects, whereas pharmacists confirm the appropriate medication dosage.

When initiating quinidine therapy, dosage adjustments may be necessary for neonates and older populations,those taking other medications such as digoxin, as well as patients with CHF, a known history of QT interval prolongation, hepatic or renal dysfunction, and those taking other medications such as digoxin. Cardiologists and intensivists provide inpatient consults, ICU care, and monitoring when hospitalization is necessary. The collective responsibilities underscore the importance of an interprofessional healthcare team approach for ensuring effective and safe therapy with quinidine.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Yang F, Hanon S, Lam P, Schweitzer P. Quinidine revisited. Am J Med. 2009 Apr;122(4):317-21. [PubMed: 19249010]

2.

Rehman MU, Shrestha B, Zehri T, Thapa S. Efficacy of Quinine versus Artemether in the treatment of severe malaria. J Nepal Health Res Counc. 2013 Jan;11(23):17-21. [PubMed: 23787519]

3.

Fralick M, Sacks CA, Kesselheim AS. Assessment of Use of Combined Dextromethorphan and Quinidine in Patients With Dementia or Parkinson Disease After US Food and Drug Administration Approval for Pseudobulbar Affect. JAMA Intern Med. 2019 Feb 01;179(2):224-230. [PMC free article: PMC6439654] [PubMed: 30615021]

4.

Xu D, Chen S, Yang J, Wang X, Fang Z, Li M. Precision therapy with quinidine of KCNT1-related epileptic disorders: A systematic review. Br J Clin Pharmacol. 2022 Dec;88(12):5096-5112. [PubMed: 35940594]

5.

Starmer CF, Grant AO, Strauss HC. Mechanisms of use-dependent block of sodium channels in excitable membranes by local anesthetics. Biophys J. 1984 Jul;46(1):15-27. [PMC free article: PMC1434933] [PubMed: 6331543]

6.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-e391. [PubMed: 29084731]

7.

Vitali Serdoz L, Rittger H, Furlanello F, Bastian D. Quinidine-A legacy within the modern era of antiarrhythmic therapy. Pharmacol Res. 2019 Jun;144:257-263. [PubMed: 31026503]

8.

Taggart WV, Holyoak W. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Clin Ther. 1983;5(4):357-64. [PubMed: 6871920]

9.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Jan 7, 2019. Quinidine. [PubMed: 30000148]

10.

Roden DM, Thompson KA, Hoffman BF, Woosley RL. Clinical features and basic mechanisms of quinidine-induced arrhythmias. J Am Coll Cardiol. 1986 Jul;8(1 Suppl A):73A-78A. [PubMed: 2423573]

11.

Benton RE, Sale M, Flockhart DA, Woosley RL. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther. 2000 Apr;67(4):413-8. [PubMed: 10801251]

12.

Ochs HR, Greenblatt DJ, Lloyd BL, Woo E, Sonntag M, Smith TW. Entry of quinidine into cerebrospinal fluid. Am Heart J. 1980 Sep;100(3):341-6. [PubMed: 7405805]

13.

Hørding M, Feldt-Rasmussen UF. [Acute iridocyclitis with fever and liver involvement during quinidine therapy]. Ugeskr Laeger. 1991 Aug 19;153(34):2362-3. [PubMed: 1897051]

14.

Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum. 1995 Apr;24(5):315-22. [PubMed: 7604299]

15.

Fisher CM. Visual disturbances associated with quinidine and quinine. Neurology. 1981 Dec;31(12):1569-71. [PubMed: 7198212]

16.

Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011 May 01;34(5):357-74. [PubMed: 21513360]

17.

Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis. 1977 Sep-Oct;20(2):151-63. [PubMed: 331400]

18.

Leahey EB, Bigger JT, Butler VP, Reiffel JA, O'Connell GC, Scaffidi LE, Rottman JN. Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiol. 1981 Dec;48(6):1141-6. [PubMed: 7304462]

19.

Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. Digoxin-quinidine interaction Pharmacokinetic evaluation. N Engl J Med. 1979 May 31;300(22):1238-41. [PubMed: 431681]

20.

Spinler SA, Cheng JW, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther. 1995 Jan;57(1):89-94. [PubMed: 7828386]

21.

Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. N Engl J Med. 1976 Mar 25;294(13):699-702. [PubMed: 1250281]

22.

Hardy BG, Schentag JJ. Lack of effect of cimetidine on the metabolism of quinidine: effect on renal clearance. Int J Clin Pharmacol Ther Toxicol. 1988 Aug;26(8):388-91. [PubMed: 3220613]

23.

Burckart GJ, Marin-Garcia J. Quinidine dosage in children using population estimates. Pediatr Cardiol. 1986;6(5):269-73. [PubMed: 3725633]

24.

Ochs HR, Greenblatt DJ, Woo E, Smith TW. Reduced quinidine clearance in elderly persons. Am J Cardiol. 1978 Sep;42(3):481-5. [PubMed: 356577]

25.

Crouthamel WG. The effect of congestive heart failure on quinidine pharmacokinetics. Am Heart J. 1975 Sep;90(3):335-9. [PubMed: 1163425]

26.

Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001 Dec 18;135(12):1047-51. [PubMed: 11747383]

27.

Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018 Feb 07;13(2):300-317. [PMC free article: PMC5967417] [PubMed: 29042465]

28.

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 09;140(2):e125-e151. [PubMed: 30686041]

29.

Cheng CM, Salazar A, Amato MG, Lambert BL, Volk LA, Schiff GD. Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs. J Am Med Inform Assoc. 2018 Jul 01;25(7):872-884. [PMC free article: PMC7647046] [PubMed: 29800453]

30.

Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021 Jul;97(1149):452-458. [PMC free article: PMC8237186] [PubMed: 33122341]

31.

Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016 Mar;81(3):420-7. [PMC free article: PMC4767204] [PubMed: 26183037]

32.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): May 10, 2018. Quinidine. [PMC free article: PMC547852] [PubMed: 31644176]

Disclosure: Ashish Jain declares no relevant financial relationships with ineligible companies.

Disclosure: JITENDRA SISODIA declares no relevant financial relationships with ineligible companies.